Bill-and-hold revenue, related parties and a whistleblower at year end

The test. Revenue can be recognised before physical delivery only where all of the following are met: a substantive reason for the bill-and-hold arrangement; the goods are separately identified as belonging to the customer; they are ready for delivery; the seller cannot use them to fulfil other orders; and delivery is probable. Meridian fails at least two:

• The products are standard and could be sold to other customers, so the goods are not set aside for the buyer and the seller retains the ability to redirect them - control has not passed.
• A 35% historical return rate on similar arrangements shows the distributors neither control the goods nor bear their risks. A 10% advance is consistent with a financing or a returns arrangement, not with a sale.

Conclusion. The ₹64 crore cannot be recognised in FY2025. Nor can a reduced amount be recognised net of expected returns: the problem is the absence of a transfer of control, not the measurement of a return provision. Reverse the revenue and the related receivable, restore inventory and reverse the cost of goods sold and any profit already taken on the goods.

Quantify the consequences before the committee decides anything

• FY2025 revenue and EBITDA fall by ₹64 crore of margin; profit follows the same route through tax.
• The covenant is tested on EBITDA. On these numbers the company is likely in breach or close to it. The breach is itself a disclosable event, may cause the term loan to be reclassified as current, and may trigger cross-default provisions. The board must talk to the lenders before it signs the accounts, not after - a waiver obtained in March is worth far more than a breach disclosed in May.
• Whether the prior year is also misstated, and whether a restatement is required.

What the committee must obtain

1. The three storage agreements, the side correspondence and the delivery records, not a management summary of them.
2. The prior-year working papers and the auditor's reasoning, to establish whether the same fact pattern was accepted before.
3. A written position from the statutory auditor, on the record, before approval.
4. A minute that records the analysis and, if the committee is outvoted at board level, the dissent.

A covenant is a consequence of the accounting. It is never a reason for it.

1. Independence of the audit committee chair. ₹0.9 crore of fees to the chair's own firm is a pecuniary relationship that must be tested against the statutory independence criteria and the listing rules, and disclosed. The test is not merely whether a threshold is crossed but whether a reasonable shareholder would see the chair as independent of the management she is meant to challenge. Whatever the test's outcome, the chair must not preside over the discussion of the related-party items, and a lead independent director should run those items. If the relationship is material, the board must re-examine the appointment and put it to shareholders.

2. The MD's son's logistics supplier. Close family of key managerial personnel is a related party. The ₹40 crore at 18% above market requires: identification and full disclosure (the related-party note and the listing-rule disclosures), audit committee approval of the transactions and of any modification, an independent benchmarking study, and recovery or renegotiation of the excess. If the terms are not at arm's length, or not in the ordinary course of business, shareholder approval is required under company law. Transaction-by-transaction approval in advance is the standard; a block approval given a year ago does not cover a new rate.

3. The CFO's brother's share purchase. The purchase on 22 March, three weeks before results and while a fraud allegation was live, is a serious insider-trading risk. Actions: freeze the trading window immediately; preserve the pre-clearance records, the code-of-conduct declarations and the brother's trading records; investigate whether the brother was in possession of unpublished price-sensitive information sourced from the CFO; remove the CFO from any role in finalising the results or dealing with the auditor until the investigation concludes; and, if the investigation confirms the flow of information, report the matter to the securities regulator. Waiting for the results to be announced before investigating is precisely the wrong sequence.

4. The whistleblower allegations. Bribery-linked discounts and related-party self-dealing are both fraud allegations. The committee must: appoint an external forensic firm reporting to the committee alone; protect the whistleblower's identity and employment; place the sales head on leave pending the outcome; preserve emails, discount approvals and payment records; and inform the statutory auditor, whose own fraud-reporting duty is triggered where fraud of ₹1 crore or more is established.

Common thread. Each matter was either known and tolerated, or not surfaced because the committee lacked the information channels to hear it. The fix is structural as well as disciplinary: a functioning whistleblower policy, a related-party register reviewed quarterly, an annual independence confirmation that lists every fee, and an audit committee that meets the auditors without management present.

My position. Withholding a known revenue overstatement and two fraud allegations until after the results is not a timing preference; it is the publication of accounts the board knows to be false. I would say so in the meeting and ask for the instruction to be recorded in the minutes.

Step 1 - do not approve the results. Convene the audit committee within 48 hours on written notice, table the whistleblower email, the storage agreements, the related-party data and the trading records, and record that the committee does not recommend the financial results for approval.

Step 2 - escalate in writing to the whole board. A letter to every director, not only the MD, setting out the issues, the accounting analysis, the disclosure obligations and the actions taken. Circulating to all directors means no colleague can later claim ignorance, and it converts a private disagreement into a documented governance process. Material developments must be disclosed to the stock exchanges promptly; unpublished price-sensitive information cannot be parked because the MD prefers it, and a selective silence while insiders trade is itself an offence.

Step 3 - protect the process and the people. Preserve records and devices; confirm the whistleblower's protection in writing; ensure the CFO and the sales head have no role in the investigation or in preparing the results; instruct the statutory auditor in writing of the allegations and ask for a written response before the audit report is signed.

Step 4 - if the board proceeds anyway.

• Refuse to sign the audit committee approval and ensure the dissent is minuted with reasons.
• Record, contemporaneously and in my own words, what I was told, when, and what I did.
• Resign as a director with a letter stating the reasons. The company must file and disclose the resignation and the reasons; the resignation letter is the shareholders' only notice that something was wrong, and a silent resignation deprives them of it.
• Consider whether any statutory duty to report arises independently, and take advice on it.

Personal exposure. A director who signs accounts she knows to be false is exposed to fraud and securities liability. Being outvoted is no defence unless the dissent is documented at the time. The choice is not between loyalty and disclosure; it is between a documented objection and personal liability. Staying on the board and saying nothing is the only option that is both ineffective and unsafe.